X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aged (3) 3
care and treatment (3) 3
female (3) 3
humans (3) 3
male (3) 3
relapse (3) 3
transplantation (3) 3
adolescent (2) 2
adult (2) 2
chemotherapy (2) 2
clinical trials (2) 2
disease-free survival (2) 2
diseases (2) 2
hematology (2) 2
index medicus (2) 2
leukemia (2) 2
middle aged (2) 2
stem cells (2) 2
survival (2) 2
survival rate (2) 2
transplants & implants (2) 2
1st relapse (1) 1
abridged index medicus (1) 1
activation (1) 1
acute gvhd (1) 1
adoptive immunotherapy (1) 1
alleles (1) 1
allogeneic bone marrow transplantation (1) 1
anemia (1) 1
anemia - chemically induced (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic agents, alkylating - administration & dosage (1) 1
antineoplastic agents, alkylating - standards (1) 1
antineoplastic agents, alkylating - toxicity (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
biology and life sciences (1) 1
blood transfusions (1) 1
bone marrow (1) 1
bone marrow transplantation - methods (1) 1
bone marrow transplantation - standards (1) 1
bone marrow transplantation, complication (1) 1
bone marrow transplantation, complication chemotherapy (1) 1
bone-marrow-transplantation (1) 1
bortezomib (1) 1
bortezomib - administration & dosage (1) 1
bortezomib - adverse effects (1) 1
busulfan (1) 1
cause of death (1) 1
cell survival (1) 1
cell transplantation (1) 1
chemoradiotherapy (1) 1
chronic granulocytic-leukemia (1) 1
chronic myelogenous leukemia (1) 1
chronic myeloid leukemia (1) 1
combination chemotherapy (1) 1
comparative analysis (1) 1
complications and side effects (1) 1
conditioning (1) 1
consolidation chemotherapy - methods (1) 1
constellations (1) 1
cyclophosphamide (1) 1
cytomegalovirus (1) 1
dexamethasone (1) 1
dexamethasone - administration & dosage (1) 1
dexamethasone - adverse effects (1) 1
disease (1) 1
disease progression (1) 1
double-blind method (1) 1
education (1) 1
end-points (1) 1
fdg-pet (1) 1
fludarabine (1) 1
follow-up studies (1) 1
free survival (1) 1
genotyping (1) 1
graft (1) 1
graft vs host disease (1) 1
graft-versus-leukemia reaction (1) 1
haplotypes (1) 1
health aspects (1) 1
health risk assessment (1) 1
hematology, oncology and palliative medicine (1) 1
hematopoietic stem cell transplantation (1) 1
hematopoietic stem cells (1) 1
hemic and lymphatic diseases (1) 1
hemopoiesis (1) 1
high-dose chemotherapy (1) 1
histocompatibility antigen hla (1) 1
hodgkin disease - drug therapy (1) 1
hodgkin disease - therapy (1) 1
hospitals (1) 1
hypertension (1) 1
hypertension - chemically induced (1) 1
immunoconjugates - adverse effects (1) 1
immunoconjugates - therapeutic use (1) 1
immunoglobulins (1) 1
immunomodulation (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9980, pp. 1853 - 1862
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Journal Article
Journal Article
Acta Haematologica, ISSN 0001-5792, 05/2001, Volume 105, Issue 2, pp. 64 - 70
A non-myeloablative conditioning protocol containing dibromomannitol (DBM/cytosine arabinoside/cyclophosphamide) has been applied to 36 chronic myeloid... 
Original Paper | Bone marrow transplantation, complication | Chemotherapy | Transplantation | Chronic myeloid leukemia | Allogeneic bone marrow transplantation | Myelosuppressive conditioning | TOTAL-BODY IRRADIATION | CHRONIC MYELOGENOUS LEUKEMIA | CHRONIC GRANULOCYTIC-LEUKEMIA | myelosuppressive conditioning | CYCLOPHOSPHAMIDE | REGIMEN | FLUDARABINE | BUSULFAN | VERSUS-HOST DISEASE | allogeneic bone marrow transplantation | transplantation | chronic myeloid leukemia | bone marrow transplantation, complication chemotherapy | STEM-CELL TRANSPLANTATION | HEMATOLOGY | ADOPTIVE IMMUNOTHERAPY | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Mitobronitol - standards | Antineoplastic Agents, Alkylating - administration & dosage | Antineoplastic Agents, Alkylating - standards | Bone Marrow Transplantation - methods | Cause of Death | Graft vs Host Disease | Mitobronitol - administration & dosage | Adult | Female | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications | Transplantation Conditioning - methods | Survival Rate | Bone Marrow Transplantation - standards | Transplantation Chimera | Disease-Free Survival | Mitobronitol - toxicity | Antineoplastic Agents, Alkylating - toxicity | Transplantation Conditioning - standards | Adolescent | Aged | Transplantation, Homologous - methods
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.